Selective COX-2 inhibition with different doses of rofecoxib does not impair endothelial function in patients with coronary artery disease

Simple item page
dc.contributor.authorTikiz C.
dc.contributor.authorÜtük O.
dc.contributor.authorBayturan O.
dc.contributor.authorBayindir P.
dc.contributor.authorEkmekçi C.
dc.contributor.authorTikiz H.
dc.date.accessioned2024-07-22T08:24:03Z
dc.date.available2024-07-22T08:24:03Z
dc.date.issued2005
dc.description.abstractIn this study, we investigated the effects of both 25 and 50 mg daily doses of rofecoxib on the endothelial functions of patients with coronary artery disease (CAD). For this purpose, 34 patients with documented severe CAD and who were under aspirin treatment (300 mg/day) were randomized to receive 4 weeks of treatment with a placebo (n = 10, group I), rofecoxib 25 mg/day (n = 12, group II), and rofecoxib 50 mg/day (n = 12, group III). Brachial artery vasodilator responses were measured in order to evaluate endothelial function. The percentage of change in endothelial-dependent vasodilation in groups I, II, and III were similar at the baseline level and showed no significant change after treatment (6.2 ± 3.9% vs. 5.9 ± 3.1% and 5.8 ± 3.3% vs. 5.6 ± 3.8% and 6.1 ± 4.5% vs. 5.8 ± 4.1%, respectively; P > 0.05). Compared with the baseline, endothelium-independent vasodilatation, as assessed by nitroglycerine (NTG), remained unchanged after the treatment period (11.2 ± 6.9% vs. 10.3 ± 7.1% and 11.2 ± 6.3% vs. 9.9 ± 5.1% and 9.5 ± 4.9% and 8.8 ± 4.6%, respectively; P > 0.05). Treatment with both doses also showed no significant effects on high-sensitivity C-reactive protein (hs-CRP) levels and resting arterial diameters (P > 0.05). In conclusion, 4 weeks of treatment with standard and high doses of rofecoxib showed no significant effects on either endothelial-dependent or independent vasodilator response or plasma hs-CRP levels in patients with severe CAD taking concomitant aspirin. Copyright©2005 by Okayama University Medical School.
dc.identifier.issn0386300X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19800
dc.language.isoEnglish
dc.subjectAged
dc.subjectBrachial Artery
dc.subjectCoronary Arteriosclerosis
dc.subjectCyclooxygenase 2
dc.subjectCyclooxygenase 2 Inhibitors
dc.subjectCyclooxygenase Inhibitors
dc.subjectDose-Response Relationship, Drug
dc.subjectEndothelium, Vascular
dc.subjectFemale
dc.subjectHumans
dc.subjectLactones
dc.subjectMale
dc.subjectMembrane Proteins
dc.subjectMiddle Aged
dc.subjectNitroglycerin
dc.subjectProstaglandin-Endoperoxide Synthases
dc.subjectSulfones
dc.subjectVasodilation
dc.subjectVasodilator Agents
dc.subjectacetylsalicylic acid
dc.subjectC reactive protein
dc.subjectcyclooxygenase 2
dc.subjectglyceryl trinitrate
dc.subjectplacebo
dc.subjectrofecoxib
dc.subjectadult
dc.subjectaged
dc.subjectartery diameter
dc.subjectarticle
dc.subjectbrachial artery
dc.subjectcell function
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectcoronary artery disease
dc.subjectdose response
dc.subjectdrug megadose
dc.subjectendothelium
dc.subjectenzyme inhibition
dc.subjectfemale
dc.subjecthuman
dc.subjectmale
dc.subjectprotein blood level
dc.subjectstatistical significance
dc.subjectvasodilatation
dc.titleSelective COX-2 inhibition with different doses of rofecoxib does not impair endothelial function in patients with coronary artery disease
dc.typeArticle

Files

Collections

Scopus Koleksiyonu